Moderna Gets Another $472M Federal Funding For Late-Stage Coronavirus Vaccine Development

Moderna Inc. MRNA announced Sunday it is receiving another $472 million funding from President Donald Trump's administration to support late-stage clinical development of its coronavirus vaccine candidate, including an expanded phase 3 study.

What Happened

The Cambridge, Massachusetts-based company was originally allocated a $483 million award, in support of its mRNA-1273 vaccine candidate, as part of its contract with the Biomedical Advanced Research and Development Authority (BARDA). Now that amount is being ratcheted up to $955 million as Moderna expects to conduct phase 3 trials with a significantly higher number of participants.

The biotechnology firm revealed that its phase 3 study, to be conducted in collaboration with the Anthony Fauci-led National Institute of Allergy and Infectious Diseases, is expected to begin Monday. The trial would include 30,000 participants in the United States.

Why It Matters

Moderna claims it's on track to deliver nearly 500 million doses of the vaccine per year, and it could scale that number up to 1 billion doses next year due to its strategic collaboration with Lonza Group AG LZAGY.

The company said it is also collaborating with Catalent Inc CTLT for fill-finish manufacturing of the vaccine at that company’s Indiana facility. 

Last week, Moderna suffered a setback in its vaccine development as it lost a bid to invalidate a key patent related to the technology for delivery of mRNA vaccines held by Arbutus Biopharma Corp ABUS.

The U.S. government is upping investments in the development, testing and production of the COVID-19 treatment. Earlier this month, it promised $1.6 billion in funding to Novavax, Inc NVAX for its vaccine’s late-stage trial, reported Politico. 

“We’re very close to the vaccine — I think we’re going to have some very good results,” Trump reportedly said Tuesday.

Price Action

Moderna shares closed 2.8% lower at $73.21 on Friday and traded about 1.1% higher in the after-hours session.

Posted In: Anthony FauciBiomedical Advanced Research and Development Authorityclinical trialCoronavirusDonald TrumpvaccineBiotechGovernmentNewsHealth CareFinancingMediaGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.